Open AccessIDIOPATHIC THROMBOCYTOPENIC PURPURA(ITP) AND ROLE OF A UNANI DRUG IN ITS MANAGEMENT. A SINGLE CASE STUDY
Author(s) -
Ahmad Sudiro,
AUTHOR_ID,
Asma Afzal,
Naquib- Ul-Islam,
AUTHOR_ID,
AUTHOR_ID
Publication year - 2022
Publication title -
international journal of advanced research
Language(s) - English
Resource type - Journals
ISSN - 2320-5407
DOI - 10.21474/ijar01/14010
Subject(s) - thrombocytopenic purpura , medicine , splenectomy , platelet , autoantibody , purpura (gastropod) , hematologic disease , disease , drug , immunology , surgery , gastroenterology , pharmacology , spleen , antibody , ecology , biology
Idiopathic Thrombocytopenic Purpura (ITP) is immune- mediated with involvement of autoantibodies, most often directed against the platelet membrane glycoprotein IIb/IIIa, which sensitise the platlet, resulting in premature removal from the circulation by cells of the reticulo-endothelial system.ITP is a blood disorder that causes a decrease in the number of platelets in the blood. Platelets help stop bleeding. So, a decrease in platelets can result in easy bruising, bleeding gums, and bleeding inside the body. The lower the platelet count, the greater the risk of bleeding. ITP may be acute or chronic. Eventhough, most cases of ITP are self-limiting, but treatment include steroids, other drugs and in resistant cases, splenectomy is the treatment option. Even though classical Unani texts has no mention of any such disease, but this disease can be discussed under the title of bleeding disorders.A single Unani drug was selected in a dosage of 500 mgs twice daily in a patient who was otherwise advised splenectomy for the disease.